Comparison between Veeda Clinical Research IPO and WeWork India IPO.
Veeda Clinical Research IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while WeWork India IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Veeda Clinical Research IPO is up to ₹0.00 Cr whereas the issue size of the WeWork India IPO is up to ₹3,000.00 Cr. The final issue price of Veeda Clinical Research IPO is and of WeWork India IPO is ₹648.00 per share.
| Veeda Clinical Research IPO | WeWork India IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹10 per share |
| Issue Price (Lower) | ₹615.00 per share | |
| Issue Price (Upper) | ₹648.00 per share | |
| Issue Price (Final) | ₹648.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ₹60.00 per share | |
| Market Lot Size | 23 shares | |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹185.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 1,30,08,128 shares | 4,62,96,296 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹3,000.00 Cr |
| Issue Size Total | 0 shares | 4,62,96,296 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹3,000.00 Cr |
Veeda Clinical Research IPO opens on , while WeWork India IPO opens on Oct 03, 2025. The closing date of Veeda Clinical Research IPO and WeWork India IPO is , and Oct 07, 2025, respectively.
| Veeda Clinical Research IPO | WeWork India IPO | |
|---|---|---|
| Anchor Bid Date | Oct 01, 2025 | |
| Issue Open | Oct 03, 2025 | |
| Issue Close | Oct 07, 2025 | |
| Basis Of Allotment (Tentative) | Oct 08, 2025 | |
| Initiation of Refunds (Tentative) | Oct 09, 2025 | |
| Credit of Share (Tentative) | Oct 09, 2025 | |
| Listing date (Tentative) | Oct 10, 2025 | |
| Anchor Lockin End date 1 | Nov 06, 2025 | |
| Anchor Lockin End date 2 | Jan 05, 2026 |
Veeda Clinical Research IPO P/E ratio is , as compared to WeWork India IPO P/E ratio of 67.75.
| Veeda Clinical Research IPO | WeWork India IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)WeWork India Management Ltd.'s revenue increased by 17% and profit after tax (PAT) rose by 194% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 33.83 | 73.56 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 48.07 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 67.75 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹8684.71 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹9.56 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | -0.02% | 63.80% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Veeda Clinical Research IPO Retail Individual Investors (RII) are offered while in WeWork India IPO retail investors are offered . Qualified Institutional Buyers (QIB) are offered in Veeda Clinical Research IPO and 1,38,71,033 shares in WeWork India IPO.
| Veeda Clinical Research IPO | WeWork India IPO | |
|---|---|---|
| Anchor Investor Reservation | 2,08,06,548 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 1,38,71,033 shares | |
| NII | 69,35,515 shares | |
| RII | 46,23,677 shares | |
| Employee | 59,523 shares | |
| Others | ||
| Total | 4,62,96,296 shares |
Veeda Clinical Research IPO subscribed in total, whereas WeWork India IPO subscribed 1.15x.
| Veeda Clinical Research IPO | WeWork India IPO | |
|---|---|---|
| QIB (times) | 1.79x | |
| NII (times) | 0.23x | |
| Big NII (times) | 0.23x | |
| Small NII (times) | 0.21x | |
| RII (times) | 0.62x | |
| Employee (times) | 1.87x | |
| Other (times) | ||
| Total (times) | 1.15x |
